Guardant Health Feb 8, 2023 UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer Feb 2, 2023 Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Jan 31, 2023 Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering Jan 30, 2023 Menarini's Orserdu, Guardant's ctDNA CDx Net FDA Approval for ESR1-Mutated Breast Cancer Patients Jan 26, 2023 Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors Premium Jan 19, 2023 Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer Jan 10, 2023 JP Morgan Healthcare Conference, Day 1: Novartis, Bristol Myers Squibb, Mirati, Johnson & Johnson Dec 21, 2022 Guardant Health, Susan G. Komen Partner to Evaluate MRD Test in Breast Cancer Dec 16, 2022 Guardant Health CRC Screening Results Spook Investors Despite Meeting Reimbursement Requirements Dec 9, 2022 Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug Dec 8, 2022 Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients Premium Nov 1, 2022 Codex Genetics Inks Distribution Deal for Guardant Health Cancer Tests in Asia Oct 19, 2022 Craig-Hallum Initiates Coverage of Guardant Health With Buy Rating Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 2, 2022 In Brief This Week: PreludeDx, Ochsner Health, Avacta Group, Guardant Health, Caris Life Sciences Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Aug 2, 2022 Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer Jul 6, 2022 Guardant Health Licenses Genomic Cancer Assays to Adicon for Testing in China May 27, 2022 Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
